Earnings Call · Q3 FY2024·2024-11-18

Q3 24EPS +77.27%·Rev n/aQ2 24EPS -8.70%·Rev n/aQ1 24EPS -34.55%·Rev n/aQ4 23EPS +37.50%·Rev n/a⚠ consensus missing

NRX Pharmaceuticals, Inc. NRXP

Matthew Duffy — Investor Relations or Communications

Jonathan Javitt — Chief Executive Officer

Richard Narido — CFO or Finance Executive

Michael Abrams — Chief Financial Officer

+9.2%1d on move date+8.8% vs SPY3d+1.7%5d+5.9%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more NRXP calls or request research access.

More NRXP calls Browse calls Request research access